Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -1,398.40%.

  • Avidity Biosciences' EBITDA Margin rose 171987.00% to -1,398.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,660.15%, marking a year-over-year increase of 2354.00%. This contributed to the annual value of -2,932.23% for FY2024, which is 74188.00% down from last year.
  • Latest data reveals that Avidity Biosciences reported EBITDA Margin of -1,398.40% as of Q3 2025, which was up 66.02% from -4,114.97% recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' EBITDA Margin registered a high of -881.73% during Q1 2021, and its lowest value of -7,368.66% during Q1 2025.
  • Over the past 3 years, Avidity Biosciences' median EBITDA Margin value was -2,664.84% (recorded in 2023), while the average stood at -3,079.16%.
  • The largest annual percentage gain for Avidity Biosciences' EBITDA Margin in the last 5 years was 171,987bps (2025), contrasted with its biggest fall of 540,862bps (2025).
  • Over the past 5 years, Avidity Biosciences' EBITDA Margin (Quarterly) stood at -2,090.93% in 2021, then spiked by 29,584bps to -1,795.09% in 2022, then crashed by 86,975bps to -2,664.84% in 2023, then slumped by 91,595bps to -3,580.79% in 2024, then soared by 171,987bps to -1,398.40% in 2025.
  • Its last three reported values are -1,398.40% in Q3 2025, -4,114.97% for Q2 2025, and -7,368.66% during Q1 2025.